Related Experiment Video

Updated: May 14, 2026

Assessing Murine Resistance Artery Function Using Pressure Myography
07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

Genetic polymorphisms of myeloperoxidase and their effect on hypertension

Yi-Chien Liu1, Chi-Jung Chung, Horng-Sheng Shiue

  • 1Department of Cardioangiology , Taipei City Hospital, Zhongxiao Branch, Taipei , Taiwan.

Blood Pressure
|February 7, 2013
PubMed

Insights

The MPO -463 GA/AA genotype is linked to increased hypertension risk. Higher BMI and diabetes further elevate this risk in individuals with the MPO -463 GA/AA genotype.

Area of Science:

  • Genetics and cardiovascular disease research
  • Host defense mechanisms and inflammatory markers

Background:

  • Myeloperoxidase (MPO) is crucial for host defense.
  • Understanding genetic predispositions to hypertension is vital for public health.

Purpose of the Study:

  • To investigate the association between a specific MPO gene polymorphism (-463 GA/AA genotype) and hypertension risk.
  • To explore the combined effects of this MPO polymorphism, Body Mass Index (BMI), and diabetes on hypertension risk.

Main Methods:

  • Case-control study involving participants from Taipei hospitals.
  • Hypertension defined as blood pressure > 140/90 mmHg or prior treatment.
  • MPO -463 polymorphism analyzed using polymerase chain reaction-restriction fragment length polymorphism.

Main Results:

  • The MPO -463 GA/AA genotype showed a 1.97-fold increased odds ratio for hypertension compared to the GG genotype.
  • Individuals with both the MPO -463 GA/AA genotype and BMI ≥ 24 kg/m(2) had a 4.60-fold increased hypertension risk.
  • Higher BMI and diabetes status were associated with a further increased hypertension risk in those with the MPO -463 GA/AA genotype.

Conclusions:

  • This study provides the first evidence linking the MPO -463 GA/AA genotype to hypertension.
  • The MPO -463 GA/AA genotype is an independent risk factor for hypertension.
  • Interactions between MPO genotype, BMI, and diabetes status significantly influence hypertension risk.

More Related Videos

The Examination of Peroxidase-Positive Leukocytes in Semen04:36

The Examination of Peroxidase-Positive Leukocytes in Semen

Published on: January 19, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...